Mary Ference-Valenta, DO
Family Medicine · Garner, NCNPI 1619041233
Payments from drug & device makers
Across 237 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$744
- Preventric Diagnostics, Inc.$647
- Boehringer Ingelheim$371
- Lilly USA, LLC$366
- AbbVie$346
- Amgen$215
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $744 |
| Preventric Diagnostics, Inc. | 2 | $647 |
| Boehringer Ingelheim | 24 | $371 |
| Lilly USA, LLC | 20 | $366 |
| AbbVie | 23 | $346 |
| Amgen | 15 | $215 |
| Abbott | 10 | $193 |
| Boston Scientific | 3 | $156 |
| Exact Sciences | 8 | $152 |
| Bausch Health US, LLC | 7 | $147 |
| Pfizer | 9 | $133 |
| Idorsia Pharmaceuticals US Inc | 6 | $114 |
| Otsuka America Pharmaceutical, Inc. | 6 | $109 |
| GSK | 6 | $97 |
| Johnson & Johnson | 8 | $95 |
| AstraZeneca | 6 | $79 |
| Merck | 6 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Gilead | 2 | $48 |
| Medtronic | 2 | $41 |
| Astellas Pharma US Inc | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
| Exeltis, USA Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,612 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $49,070 |
| OzempicSemaglutide | 29 | $38,866 |
| JanuviaSitagliptin Phosphate | 24 | $22,850 |
| FarxigaDapagliflozin Propanediol | 21 | $22,327 |
| EliquisApixaban | 16 | $18,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,698 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $11,845 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $7,879 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,398 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $6,227 |
| SynthroidLevothyroxine Sodium | 47 | $3,065 |
| Atorvastatin Calcium | 340 | $2,816 |
| Metoprolol Succinate | 146 | $2,319 |
| BystolicNebivolol Hcl | 12 | $2,200 |
| Lisinopril | 219 | $2,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $371 | $49,07033 claims |
| Novo NordiskOzempic | $744 | $38,86629 claims |
| MerckJanuvia, Janumet Xr | $79 | $34,69535 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $97 | $31,32346 claims |
| AstraZenecaFarxiga | $79 | $22,32721 claims |
| PfizerEliquis | $133 | $18,58416 claims |
| AbbVieSynthroid | $346 | $3,06547 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $24 | $2,20012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Garner
- Domingo Rodriguez-CueGarner$253K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.